High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy.

OBJECTIVES To determine the incidence of active tuberculosis in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative drug injectors with cutaneous anergy and to examine the effectiveness of isoniazid chemoprophylaxis in preventing tuberculosis among drug injectors with positive tuberculin test results. DESIGN AND SETTING Prospective observational study linked to an ongoing study of HIV infection within a New York City (NY) methadone program; subjects also underwent routine intradermal tuberculin testing and multiple-antigen delayed-type hypersensitivity skin testing. The 31-month study period ended December 31, 1990. METHODS Anergic subjects and tuberculin reactors who were HIV seropositive were compared by HIV disease status and CD4+ T-lymphocyte levels. Tuberculosis incidence was calculated for anergics (none treated with isoniazid) and for treated and untreated tuberculin reactors, by HIV serological status. RESULTS Among those seropositive for HIV, anergic subjects had more advanced HIV disease and fewer CD4+ cells (median 0.33 vs 0.56 x 10(9)/L, P less than .01) compared with tuberculin reactors, although neither clinical status nor CD4+ cell counts consistently predicted anergy. Five (7.6%) of 68 anergic subjects who were HIV seropositive and none of 52 anergic subjects who were HIV seronegative (n = 18) or of unknown (n = 34) HIV serological status developed active tuberculosis during the study period (P less than .05). The tuberculosis incidence rate among anergic subjects who were HIV seropositive was 6.6 cases per 100 person-years (95% confidence interval [Cl], 2.1 to 15.3). Of 25 HIV-seropositive tuberculin reactors who did not receive or complete 12 months of isoniazid prophylaxis, tuberculosis incidence was 9.7 cases per 100 person-years (95% Cl, 2.6 to 24.7; P = 0.56, compared with the rate among anergic HIV seropositives); there were no cases of tuberculosis in 53.4 person-years of follow-up for 27 HIV-seropositive tuberculin reactors who received 12 months of prophylaxis (rate difference between treated and untreated groups, 9.7 cases per 100 person-years, 95% Cl, 1.3 to 18.0). CONCLUSION Drug injectors with cutaneous anergy who are seropositive for HIV are at high risk of active tuberculosis, similar to that among untreated HIV-seropositive tuberculin reactors. A decreased incidence of active tuberculosis was seen in HIV-seropositive tuberculin reactors receiving 12 months of isoniazid chemoprophylaxis, compared with untreated or partially treated subjects. These results support the routine use of delayed-type hypersensitivity testing to accompany tuberculin testing for drug injectors with known or suspected HIV infection, and consideration of isoniazid prophylaxis for anergic as well as tuberculin-reactive subjects who are HIV seropositive, in populations with a high prevalence of coexisting HIV and Mycobacterium tuberculosis infection.

[1]  G. Schoolnik,et al.  An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. , 1992, The New England journal of medicine.

[2]  D. Vlahov,et al.  Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. , 1992, JAMA.

[3]  T. Jordan,et al.  Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. , 1991, JAMA.

[4]  D. Snider,et al.  Tuberculosis in patients with human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[5]  Selwyn Pa.  Tuberculosis in the AIDS era: a new threat from an old disease. , 1991 .

[6]  R. Chaisson,et al.  Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[7]  D E Snider,et al.  Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. , 1990, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[8]  E. Nardell,et al.  Dodging droplet nuclei. Reducing the probability of nosocomial tuberculosis transmission in the AIDS era. , 1990, The American review of respiratory disease.

[9]  A. Pitchenik.  Tuberculosis control and the AIDS epidemic in developing countries. , 1990, Annals of internal medicine.

[10]  R. Luzzati,et al.  NOSOCOMIAL EPIDEMIC OF ACTIVE TUBERCULOSIS AMONG HIV-INFECTED PATIENTS , 1989, The Lancet.

[11]  B. Hirschel,et al.  Tuberculin skin reactivity in HIV-seropositive intravenous drug addicts. , 1989, The New England journal of medicine.

[12]  P. Selwyn,et al.  Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. , 1989, Annals of internal medicine.

[13]  P. Selwyn,et al.  Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. , 1989, American journal of public health.

[14]  P. Selwyn,et al.  Risk factors for human immunodeficiency virus infection in intravenous drug users. , 1989, The New England journal of medicine.

[15]  D. Snider,et al.  Tuberculosis in the United States , 1989, Nature.

[16]  S. Vermund,et al.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[17]  P. Selwyn,et al.  Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. , 1988, AIDS.

[18]  T. Maniatis,et al.  Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS). , 1986, JAMA.

[19]  A. Okwera,et al.  Tuberculin reactions in apparently healthy HIV-seropositive and HIV-seronegative women--Uganda. , 1990, MMWR. Morbidity and mortality weekly report.

[20]  R. Chaisson,et al.  Tuberculosis and human immunodeficiency virus infection. , 1989, The Journal of infectious diseases.